Serum Institute of India launches HIB vaccine in India

RELATED NEWS Biotech industry exports grow 47% to touch US$ 1.2bn Shantha Biotechnics triples vaccine filling capacity New vaccine for cancer lesions Nifty BSE | NSE 10/02/12 Are Mutual Funds betting on Nifty?

Serum Institute of India Ltd, India's largest vaccine manufacturer announced the launch of its indigenously manufactured low-cost Haemophilus influenza type b conjugate vaccine under the brand name of "HibPRO" in India. HibPRO has been priced at MRP Rs 375/- for a monodose vial. HibPRO is a vaccine with clinically proven efficacy & safety at an affordable price; hence it is a world class vaccine at Indian price.

 

Haemophilus influenza causes infections that are a major cause of morbidity and mortality in young children spreading through droplets. Children below 5 years of age are at highest risk of the disease & is rarely seen after 5 years of age. Every year globally around 3 to 5 lakhs children die due to H. influenza type b disease. HIB vaccines are safe and highly effective.

 

According to Dr. Cyrus Poonawalla, Chairman, Serum Institute of India Ltd.: "HibPRO has undergone series of clinical trials to prove its efficacy and safety in comparison with commercially available Hib conjugate vaccines. With the launch of HibPRO serum can extend the benefits of Pentavalent or Quadravalent vaccines at a very affordable price. These benefits are mainly fewer numbers of injections, lesser pain to the child and protection against multiple diseases such as H. influenza type b, Hepatitis-B, Diphtheria, Pertussis and Tetanus in one injection." 

 

Sourced From: Adfactors Public Relations Pvt Ltd